Key statistics
As of last trade, Neurocrine Biosciences Inc (NB3:BER) traded at 118.70, 18.82% above the 52 week low of 99.90 set on Nov 22, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 118.70 |
---|---|
High | 118.70 |
Low | 118.70 |
Bid | 120.95 |
Offer | 121.35 |
Previous close | 116.20 |
Average volume | 63.44 |
---|---|
Shares outstanding | 101.25m |
Free float | 100.03m |
P/E (TTM) | 33.47 |
Market cap | 12.66bn USD |
EPS (TTM) | 3.73 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 07:08 GMT.
More ▼
- Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules
- Neurocrine Biosciences to Participate at Investor Conferences in November
- Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules
- Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia
- Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
- Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results
- Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
- Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
- Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia
- Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
More ▼